Current behavior of sudden cardiac arrest and sudden death

Comportamiento actual del paro cardíaco súbito y muerte súbitos

Humberto Rodríguez-Reyes*, Mayela Muñoz-Gutiérrez, and José L. Salas-Pacheco

Department of Research, Sociedad Cardiovascular y Arritmias (SOCAyA), Aguascalientes, Mexico

Abstract

Sudden cardiac arrest (SCA) and sudden death (SD) continue to be a global public health problem, although the true incidence is unknown, it is estimated that they are responsible for 30% of cardiac origin mortality and may represent 20% of total mortality in adults. Unfortunately, the majority of cases occur in the general population, at the out-of-hospital level, in homes and in people who were not known to have heart disease. Although the majority of SCA victims are considered to be of cardiac origin and more frequent ischemic, it is not possible to rule out other causes only with the clinical diagnosis. Autopsy, histological, and toxicological studies are necessary in all victims of SCA and SD to determine the precise cause of death; when these studies are carried out, causes of non-cardiac origin have been found in up to 40% of victims. The type of arrhythmia responsible for an episode of SCA and SD has changed over the years, now asystole and pulseless electrical activity are detected more frequently than ventricular fibrillation or pulseless ventricular tachycardia. These and other aspects that we consider important in the current behavior of SCA and SD are analyzed in this article.

Key words: Sudden cardiac arrest Sudden death. Asistolia. Electric activity without pulse. Ventricular fibrillation. Pulseless ventricular tachycardia.

Resumen

El paro cardíaco súbito (PCS) y la muerte súbita (MS) continúan siendo un problema de salud pública mundial; aunque su verdadera incidencia se desconoce, se calcula que producen el 30% de la mortalidad de origen cardíaco y pueden representar el 20% de la mortalidad total en los adultos. Desafortunadamente, la mayor parte de los casos se presenta en la población general, de forma extrahospitalaria, en los hogares y en personas que no se conocían portadoras de cardiopatía. Aunque se considera que la mayoría de las víctimas de PCS es de origen cardíaco, y que es más frecuente el isquémico, no es posible descartar otras causas sólo con el diagnóstico clínico. Son necesarios la necropsia y los estudios histológicos y toxicológicos en todas las víctimas de PCS y MS para determinar la causa precisa de la muerte; cuando estos estudios se efectúan se han encontrado causas de origen no cardíaco hasta en 40% de las personas. El tipo de arritmia causante de un episodio de PCS y MS ha cambiado a través de los años; ahora se detectan con mayor frecuencia asistolia y actividad eléctrica sin pulso (AES) que la fibrilación ventricular (FV) o la taquicardia ventricular sin pulso (TVSP). Estos y otros aspectos de importancia en el comportamiento actual del PCS y la MS se analizan en este artículo.

Introduction

In adults, sudden cardiac arrest (SCA) is one of the main signs of heart disease, with symptomatic or asymptomatic ischemic heart disease being considered to be the cause of most cases\(^1\)-\(^3\). SCA occurs when the heart suddenly and unexpectedly stops pumping blood; the victim loses the state of alertness, has no signs of circulation and only gasps; without treatment, this abnormality leads to sudden death (SD). Some individuals with SD may have previous symptoms, such as chest pain, dyspnea, syncope, pre-syncope, or seizures, but often they go unnoticed\(^4\). SD is also suspected in people who had been seen alive within a period not longer than 24 h and then were found lifeless in the absence of an obvious cause of death, such as those cases identified at dawn without an observer\(^5\),\(^6\). It is a public health problem worldwide\(^7\); SD is estimated to account for 30% of cardiovascular mortality, and for 20% of deaths in adults\(^8\)-\(^10\). The true incidence of SCA and SD is unknown, and there are variations according to the studied population; in China, Europe, and USA, 41, 86, and 155 cases have been reported per 100,000 population/year, respectively\(^11\)-\(^13\). In the population younger than 35 years, an incidence of 1-3 cases/100,000 population/year is considered\(^14\), and at 75 years of age, 800 cases/100,000 population/year\(^13\),\(^15\). In 2015, 17.7 million of deaths associated with cardiovascular diseases were reported in the world\(^16\); 30% of these are likely to be due to SCA and SD, which can represent up to 5.31 million cases/year (Table 1).

Causes according to age groups

The causes vary with regard to age groups; in people older than 25 years, symptomatic or asymptomatic coronary artery disease is the main cause\(^8\),\(^10\),\(^14\). From 20 to 40% of cases can be secondary to cardiomyopathies due to systemic arterial hypertension, obesity, diabetes, alcohol, as well as to idiopathic, valvular, congenital, infiltrative, non-compacted myocardial fibrosis, or heart failure\(^8\),\(^10\),\(^13\). Slightly more than 50% of adults with SCA and SD have no previous diagnosis of structural heart disease, only a high prevalence of cardiovascular risk factors, especially systemic arterial hypertension, diabetes mellitus, sedentary lifestyle, smoking, obesity, and dyslipidemia\(^6\),\(^8\). In few cases, SD is consecutive to primary arrhythmic disease in adults\(^5\),\(^6\). In those younger than 25 years, the main causes are hypertrophic cardiomyopathy, congenital anomalies of the coronary arteries, arrhythmogenic cardiomyopathy, and primary arrhythmic disease, such as Wolff-Parkinson-White syndrome, long QT syndrome, Brugada syndrome, short QT syndrome, catecholaminergic polymorphic ventricular tachycardia, and idiopathic ventricular fibrillation (VF)\(^14\),\(^17\). Unfortunately, the exact cause of death is unknown in most cases and only undergo verification by anatomopathological, histological, or toxicological examination; the diagnosis of cardiac-origin SD (CSD) is almost always a clinical approach, which overestimates the causes and the incidence\(^18\),\(^19\). A recent study of 525 people with CSD, with a mean age of 62.8 years and with 69% of males, identified non-cardiac-origin causes in 40% of cases (40%, drug overdose; 60%, opiates; 14%, neurological causes; 11%, infectious causes; 9% pulmonary embolism; and 7%, gastrointestinal bleeding)\(^18\). Another study of 1039 CSD victims with a mean age of 32 years (66% males), identified that 28% of cases were due to non-cardiac-origin causes (40%, pulmonary; 20%, infectious; 18%, cerebrovascular; and 8% other neurological diseases)\(^19\). Recently, the American Heart Association (AHA), the American College of Cardiology and the Heart Rhythm Society have recommended the performance necropsy studies in all SCA and SD victims, to confirm the diagnosis and find the exact causes of death\(^20\).

Table 1. SD in adults worldwide, calculated causes, and survival

<table>
<thead>
<tr>
<th>Causes</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ischemic heart disease</td>
<td>60-80%</td>
</tr>
<tr>
<td>Cardiomyopathies (hypertrophic, dilated, valvular, etc.)</td>
<td>20-40%</td>
</tr>
<tr>
<td>Primary arrhythmogenic disease</td>
<td>1-2%</td>
</tr>
<tr>
<td>Detected arrhythmias</td>
<td></td>
</tr>
<tr>
<td>Asystole</td>
<td>40-50%</td>
</tr>
<tr>
<td>PEA</td>
<td>30%</td>
</tr>
<tr>
<td>VF/PVT</td>
<td>20%</td>
</tr>
<tr>
<td>Out-of-hospital cases</td>
<td></td>
</tr>
<tr>
<td>At home</td>
<td>70-80%</td>
</tr>
<tr>
<td>In public areas</td>
<td>20%</td>
</tr>
<tr>
<td>Without observer</td>
<td>50-60%</td>
</tr>
<tr>
<td>Overall survival</td>
<td>&lt; 10%</td>
</tr>
</tbody>
</table>

PEA: pulseless electrical activity; VF: ventricular fibrillation; PVT: pulseless ventricular tachycardia.

Causal arrhythmias

Over the years, the type of arrhythmias causative of a SD episode has changed; previously, VF and pulseless ventricular tachycardia (PVT) were recognized as the
main origins, but currently, asystole, and pulseless electrical activity (PEA) are recorded more frequently. VF and PVT appear to be the most common causes of SCA and SD in cases that occur away from home and in those related to physical activity. In the general population, asystole has been found in 40-50%, PEA in 30%, and VF/PVT in 20% of cases.

Malignant arrhythmia substrates

For malignant arrhythmias to occur, the participation of substrates and activators acting on the heart is required. The most important substrates are myocardial ischemia, myocardial fibrosis, and ion channel abnormalities (congenital or acquired). Myocardial ischemia favors the dispersion of refractory periods and the presence of activity in ventricular myocardial cells. Myocardial fibrosis gives rise to the development of ventricular reentry circuits, and ion channel abnormalities, to ventricular depolarization and repolarization alterations.

Malignant arrhythmia activators

In all SCA and SD victims, the participation of substances, drugs, or metabolic alterations that work as activators and that can be the origin of the episode should be ruled out. Malignant arrhythmia triggering factors that may be involved (Fig. 1) are various: (a) increased activity of the sympathetic and parasympathetic nervous system, of the renin-angiotensin system and increase in the number of circulating catecholamines; (b) hemodynamic factors such as end-diastolic pressure, afterload, and left ventricle parietal stress elevation; (c) hydroelectrolytic alterations such as hypokalemia, hypocalcemia or hypomagnesemia; (d) metabolic disturbances such as dehydration, acidosis, hyperglycemia, or hypoglycemia; (e) hypoxia; (f) iatrogenic factors secondary to the use of drugs such as diuretics, inotropics, vasodilators, anti-arrhythmic agents, or drugs that prolong the QT interval or cause Brugada pattern; (g) drugs and addictive substances such as alcohol, tobacco, cocaine, cannabis, heroin, caffeine, guarana, and other stimulating substances; (h) energy drinks with high content of sugar, caffeine, guarana, and other stimulating substances; (i) excessive exercise; and (j) psychosocial stress, specially anxiety, and depression.

Clinical characteristics and risk group

Based on SCA and SD victims clinical characteristics, the population is classified into three groups, as
shown in table 2: group I, population with risk factors for ischemic heart disease, but without a diagnosis of the previous heart disease6,6,9,10; Group II, carriers of some structural heart disease1-3, chronic lung disease29, sleep apnea30 or kidney failure31; and Group III, survivors of a SCA episode or arrhythmic death high-risk carriers32. Symptomatic or asymptomatic myocardial ischemia is the most important risk factor for developing SCA and SD in adults1-3. In patients diagnosed with ischemic heart disease, those of the male gender, who are smokers and have persistent ST-segment elevation with frequent ventricular extrasystoles are at increased risk of SCA and SD33, as it occurs in patients in whom increased myocardial ischemia, myocardial fibrosis, or total occlusion of the coronary artery related to a heart attack have been detected6. Heart failure (HF) patients with left ventricular ejection fraction (LVEF) lower than 30% have a high risk of dying from SCA and SD34. LVEF as the only arrhythmic-origin SD predictor is insufficient; the Seattle classification helps recognize arrhythmic death high-risk carriers who can benefit from an automated implantable cardioverter defibrillator (AICD)35. Figure 2 shows the clinical characteristics related to higher risk of SCA and SD and that confer higher possibility of response to the implantation of an AICD in patients with HF of ischemic or non-ischemic origin (modified from Levy et al.33).

Table 2. SCA and SD victims clinical characteristics.

<table>
<thead>
<tr>
<th>Group</th>
<th>Characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group 1</td>
<td>General population with risk factors for ischemic heart disease such as:</td>
</tr>
<tr>
<td></td>
<td>Systemic arterial hypertension, diabetes mellitus, smoking, obesity, dyslipidemia, and sedentary lifestyle</td>
</tr>
<tr>
<td>Group 2</td>
<td>Structural heart disease</td>
</tr>
<tr>
<td></td>
<td>Ischemic, hypertrophic, dilated, valvular, congenital, infiltrative heart disease, non-compacted, arrhythmogenic cardiomyopathy, heart failure, abnormalities in the origin or trajectory of coronary arteries, and congenital heart diseases.</td>
</tr>
<tr>
<td></td>
<td>Kidney failure, chronic pulmonary disease, or sleep apnea</td>
</tr>
<tr>
<td></td>
<td>Primary arrhythmogenic disease</td>
</tr>
<tr>
<td></td>
<td>Wolff-Parkinson-White, long QT, and Brugada syndromes, malignant early repolarization, catecholaminergic polymorphic VT (CPVT), and short QT syndrome</td>
</tr>
<tr>
<td>Group 3</td>
<td>Subjects recovered from SCA or with a history of VF, VT, or syncope secondary to ventricular arrhythmias idiopathic VT or VF</td>
</tr>
</tbody>
</table>

Any patient in these groups is considered to be at higher risk and having a family history of SD should be a reason for more exhaustive examination.

Figure 2. Clinical characteristics according to the scale of Seattle and their relationship with the mode of death and response to an automated implantable cardioverter defibrillator in patients with heart failure of ischemic or non-ischemic origin (modified from Levy et al.33).

Symptoms before an episode of SCA and SD

There is evidence that, in children and adults with SCA, the previous symptoms are common41,42. In children, 26-33% of victims had some type of symptom,
Table 3. Sequence of steps for the care of the SCA victim in the community; manual-only CPR and use of public-access AED

1. Recognize the victim in cardiac arrest (suddenly collapses, does not respond, does not breathe, is pale or livid).
2. Give notice to local emergency number (in Mexico, 911), request an AED, put the call on speaker for assistance.
3. Start compressions at the center of the chest, between the two nipples from 100 to 120 x’, 5 to 6-cm deep in adults and 4 to 5 cm in children, until AED or assistance arrival.
4. Quickly use the AED:
   - Open the AED and follow the instructions
   - Place the patches as directed, use pediatric patches in children younger than 8 years, do not touch the victim while the AED analyzes
   - Warn: “Clear, nobody touch the victim”, before applying the discharge
   - Apply the discharge on the button that blinks
5. Restart compressions until the patient recovers, assistance arrives, or AED indicates and in 45% of cases, symptoms had occurred even 40 days before the episode; the most common symptoms were chest pain, seizures of unknown causes, dyspnea, and syncope. In adults, up to 50% of victims had previous symptoms and men suffered chest pain more often, while women experienced dyspnea. Subjects with SCA who experienced symptoms and requested help or sought medical care before the event, significantly improved survival in comparison with those who did not ask for help (32% vs. 6%).

SCA treatment in the community

Specific treatment of a SCA victim includes cardiopulmonary resuscitation (CPR) maneuvers and the use of an automated external defibrillator (AED); table 3 shows the steps to follow for the care of SCA in the community. The earlier CPR is applied and AED used, the higher the survival likelihood of those affected by SCA. In the cases of VF and PVT, which occur more frequently away from home, early defibrillation highly significantly improves the survival rates (Fig. 3); when CPR is started and defibrillation is carried out within the first 2 min after SCA occurrence, survival rates of up to 71% can be achieved, with good neurological recovery. Within the 1st min, ventricular defibrillation success is higher than 90%, and it drops by 7-10%/min without CPR. The latter prolongs the time window for the possibility to perform successful defibrillation. The AHA CPR guidelines, as well as studies in the general population, emphasize the importance for both the general public and health personnel to be trained and have the knowledge to perform high quality CPR and use an AED. Exclusively manual compressions and the use of public access AED have been shown to be highly effective for improving SCA victims survival in the community. There are important limitations for the treatment of people with SCA occurring at home, where most cases are recorded; the most commonly detected rhythms are asystole and PEA; the possibilities of early detection and treatment are reduced and treatment success is much lower than that achieved in cases with VF and PVT. In Mexico, some cases of SCA victims survival have been reported, when the survival chain is properly implemented, and the creation of a comprehensive care system for individuals with SCA is strongly recommended.

Conclusions

SCA and SD are a global public health problem. Unfortunately, almost all cases occur in the general population, in out-of-hospital settings, at home and in people who were unaware of being heart disease bearers. True incidence and prevalence are unknown. Carrying out anatomopathological, histological and toxicological studies in all people with SD is advisable to find the exact cause of death, which will help the provision of better prevention measures. At present, the most commonly identified arrhythmias are asystole and PEA. Symptoms before a SCA occur in up to 33% of children and 50% of adults; when victims seek medical attention before experiencing the episode, survival is significantly improved. High-quality CPR and AED use are SCA initial treatment; in the cases of VF and PVT, AED early use substantially improves survival; health personnel and the general population should know and apply these measures. Favoring manual-only CPR and
AED use programs in the community to reduce SCA mortality is advisable. Further research and prevention measures applied to the general population are needed to reduce the incidence of SCA and SD.

**Acknowledgment**

The authors express their gratitude to their patients and coworkers in the cardiology field, who are the reason for this review.

**Funding**

The authors received no sponsoring to carry out this document.

**Conflicts of interest**

The authors declare that they have no conflicts of interest.

**Ethical disclosures**

Protection of people and animals. The authors declare that no experiments were performed on humans or animals for this investigation.

Confidentiality of data. The authors declare that they have followed the protocols of their work center on the publication of patient data.

Right to privacy and informed consent. The authors declare that no patient data appear in this article.

**References**


